Latest Breaking News On - Menin inhibitor - Page 1 : comparemela.com

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited kingdomAnn hematolJianxiang wangZhou yiShui weiBen atwell alex shawUnited kingdom medical research councilStock exchange of hong kongExchange commissionChina limitedNational cancer institutePhasei trialMenin inhibitorHematological malignanciesChinese academy

Kura Oncology to Participate in SVB Securities Global

SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the.

Troy wilsonAlexandra weingartenKura oncology incCorporate communicationsGlobal biopharmaChief executive officerBreakthrough therapy designationVice presidentInvestor relationsNasdaq kuraKura oncologyPrecision medicineMenin inhibitorFarnesyl transferase inhibitor

Kura Oncology Presents Updated Clinical Data from KOMET-001

– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥.

United statesHarry erbaRoberth uhlTroy wilsonStephen daleDuke cancer instituteDrug administrationCompany formExchange commissionAmerican society of hematologyKura oncology incCorporate communicationsLeukemia programAmerican societyDuke cancerProject optimus

Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias

- 30% CR/CRh rate and 53% ORR in R/R acute leukemia patients with NPM1 or MLLr (KMT2Ar) mutations; no discontinuations due to treatment-related adverse events.

United statesGhayas issaSharon klahreMichaela metzgerCompany on twitterSyndax pharmaceuticalsEuropean commissionDrug administrationExchange commissionAmerican society of hematologyInternational numberPrnewswire syndax pharmaceuticals incSyndax pharmaceuticals incAmerican societyAnnual meetingChief executive

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219 s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219 s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesThomas butlerVan sandwickdirectorExchange commissionInvestor relations corporate developmentSecurities exchangeAmerican diabetes associationBiomea fusion incWall streetScientific sessionsChief executive officerPresentation detailsMenin inhibitorDurable reductionMellitus ratZucker diabetic fatty rat